- Home
- CB vs BMY Comparison
CB vs BMY Comparison
Compare CB & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CB
- BMY
- Stock Information
- Founded
- CB 1985
- BMY 1887
- Country
- CB Switzerland
- BMY United States
- Employees
- CB N/A
- BMY N/A
- Industry
- CB Property-Casualty Insurers
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- CB Finance
- BMY Health Care
- Exchange
- CB Nasdaq
- BMY Nasdaq
- Market Cap
- CB 114.8B
- BMY 120.5B
- IPO Year
- CB 1993
- BMY N/A
- Fundamental
- Price
- CB $292.33
- BMY $59.19
- Analyst Decision
- CB Buy
- BMY Hold
- Analyst Count
- CB 16
- BMY 14
- Target Price
- CB $301.13
- BMY $58.00
- AVG Volume (30 Days)
- CB 2.0M
- BMY 12.9M
- Earning Date
- CB 04-22-2025
- BMY 04-24-2025
- Dividend Yield
- CB 1.25%
- BMY 4.19%
- EPS Growth
- CB 4.13
- BMY N/A
- EPS
- CB 22.70
- BMY N/A
- Revenue
- CB $55,882,000,000.00
- BMY $48,300,000,000.00
- Revenue This Year
- CB N/A
- BMY N/A
- Revenue Next Year
- CB $5.52
- BMY N/A
- P/E Ratio
- CB $12.84
- BMY N/A
- Revenue Growth
- CB 12.45
- BMY 7.32
- 52 Week Low
- CB $238.85
- BMY $39.35
- 52 Week High
- CB $302.05
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- CB 58.45
- BMY 48.76
- Support Level
- CB $289.22
- BMY $59.46
- Resistance Level
- CB $299.33
- BMY $61.34
- Average True Range (ATR)
- CB 5.45
- BMY 1.61
- MACD
- CB -0.32
- BMY -0.11
- Stochastic Oscillator
- CB 61.89
- BMY 16.70
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.